BioLineRx is trading 5.8% down at $2.92 today as the stock gives back recent gains amid a broader biotechnology sector pullback.
- The decline aligns with ongoing weakness in small-cap biotech stocks, reflected in the downward movement of the XBI ETF.
- Today's price action appears to be driven by sector-wide risk-off sentiment rather than any new company-specific developments.